Circadian Rhythm Dysfunction in CBS/PSP

Migration, Crosslink

📖

Circadian Rhythm Dysfunction in CBS/PSP

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-cbs-psp-circadian-rhythm-d

📖 Wiki Page

disease3246 wordssynced 2026-04-02

Circadian Rhythm Dysfunction in CBS/PSP

Introduction

Circadian rhythm dysfunction is a significant and often underappreciated feature of [corticobasal syndrome (CBS)](/diseases/corticobasal-degeneration) and [progressive supranuclear palsy (PSP)](/diseases/progressive-supranuclear-psp), two related [4R tauopathies](/mechanisms/4r-tauopathies)[@litvan1996]. These neurodegenerative disorders not only cause motor and cognitive decline but also profoundly disrupt the body's internal clock system, leading to [sleep-wake cycle](/mechanisms/sleep-wake-cycle) disturbances, [melatonin secretion](/mechanisms/melatonin-circadian) abnormalities, and downstream effects on [autonomic function](/mechanisms/autonomic-dysfunction)[@cortese2020]. Understanding circadian dysfunction in these conditions is critical for comprehensive patient care, as it significantly impacts quality of life, symptom severity, and treatment outcomes.

The [suprachiasmatic nucleus](/brain-regions/suprachiasmatic-nucleus) (SCN), often called the "master clock," is the central coordinator of circadian rhythms in mammals. In CBS and PSP, [tau pathology](/mechanisms/tau-pathology) specifically targets brain regions essential for circadian regulation, creating a unique intersection between neurodegeneration and chronobiology[@swaab1985]. This page examines the mechanisms, clinical manifestations, and therapeutic approaches to circadian rhythm dysfunction in these atypical parkinsonian disorders.

The Circadian System and Neurodegeneration

Suprachiasmatic Nucleus Involvement

...

Circadian Rhythm Dysfunction in CBS/PSP

Introduction

Circadian rhythm dysfunction is a significant and often underappreciated feature of [corticobasal syndrome (CBS)](/diseases/corticobasal-degeneration) and [progressive supranuclear palsy (PSP)](/diseases/progressive-supranuclear-psp), two related [4R tauopathies](/mechanisms/4r-tauopathies)[@litvan1996]. These neurodegenerative disorders not only cause motor and cognitive decline but also profoundly disrupt the body's internal clock system, leading to [sleep-wake cycle](/mechanisms/sleep-wake-cycle) disturbances, [melatonin secretion](/mechanisms/melatonin-circadian) abnormalities, and downstream effects on [autonomic function](/mechanisms/autonomic-dysfunction)[@cortese2020]. Understanding circadian dysfunction in these conditions is critical for comprehensive patient care, as it significantly impacts quality of life, symptom severity, and treatment outcomes.

The [suprachiasmatic nucleus](/brain-regions/suprachiasmatic-nucleus) (SCN), often called the "master clock," is the central coordinator of circadian rhythms in mammals. In CBS and PSP, [tau pathology](/mechanisms/tau-pathology) specifically targets brain regions essential for circadian regulation, creating a unique intersection between neurodegeneration and chronobiology[@swaab1985]. This page examines the mechanisms, clinical manifestations, and therapeutic approaches to circadian rhythm dysfunction in these atypical parkinsonian disorders.

The Circadian System and Neurodegeneration

Suprachiasmatic Nucleus Involvement

The [suprachiasmatic nucleus](/brain-regions/suprachiasmatic-nucleus) is a small, paired structure located in the anterior [hypothalamus](/brain-regions/hypothalamus) above the optic chiasm. It contains approximately 20,000 neurons that generate endogenous circadian rhythms with a period of approximately 24 hours[@ralph1990]. The SCN synchronizes peripheral clocks throughout the body through neural, hormonal, and behavioral outputs, regulating [sleep-wake cycle](/mechanisms/sleep-wake-cycle)s, body temperature, hormone secretion, and [autonomic function](/mechanisms/autonomic-dysfunction).

In PSP and CBS, [tau pathology](/mechanisms/tau-pathology) extends to the [suprachiasmatic nucleus](/brain-regions/suprachiasmatic-nucleus) and adjacent hypothalamic regions[@jun2019]. Neuropathological studies have demonstrated:

Tau-positive [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles) in the SCN of PSP patients[@dickson2010]
Neuronal loss in the ventrolateral SCN, which receives direct retinal input
Gliosis and microglial activation in hypothalamic regions controlling circadian function
Disruption of vasopressin-secreting neurons, which are critical for SCN signaling

The involvement of the SCN in PSP was first recognized in early neuropathological descriptions, where researchers noted that the disease "could be conceived as a system degeneration affecting the rostral brainstem and diencephalon"[@steele1964]. More recent studies using advanced [neuroimaging](/diagnostics/mri-neurodegeneration) have confirmed [hypothalamic atrophy](/brain-regions/hypothalamus) in vivo, correlating with circadian dysfunction severity[@harda2018].

Neural Circuitry Affected

Mermaid diagram (expand to render)

The circadian system involves extensive neural circuitry that becomes compromised in CBS and PSP:

Retinohypothalamic tract: Direct photic input to the SCN via [melanopsin](/proteins/melanopsin)-containing [retinal ganglion cells](/cell-types/retinal-ganglion-cells)

Geniculohypothalamic tract: Secondary visual input from the intergeniculate leaflet

Brainstem neuromodulatory centers: Locus coeruleus (noradrenergic) and [dorsal raphe](/brain-regions/dorsal-raphe-nucleus) (serotonergic) projections to the SCN

Hypothalamic output pathways: Tuberoinfundibular, tuberal, and [posterior hypothalamic nuclei](/brain-regions/hypothalamus)

In PSP and CBS, [tau pathology](/mechanisms/tau-pathology) affects multiple nodes of this circuitry, including the SCN itself, the [locus coeruleus](/cell-types/locus-coeruleus-alpha), the [dorsal raphe](/brain-regions/dorsal-raphe-nucleus) nuclei, and hypothalamic autonomic centers["@braak1990"]. This widespread involvement explains the multi-faceted nature of circadian dysfunction in these disorders.

Melatonin Secretion Alterations

Melatonin Biology

Melatonin (N-acetyl-5-methoxytryptamine) is the primary hormonal output of the circadian system. Secreted by the pineal gland during darkness, melatonin serves as a "darkness signal" that coordinates peripheral circadian clocks and promotes sleep onset[@cajochen1999]. Melatonin secretion follows a robust circadian pattern, with levels remaining low during daylight hours and rising sharply in the evening, typically between 21:00-03:00.

The melatonin rhythm is driven by the SCN through sympathetic innervation of the pineal gland via the superior cervical ganglion. Any disruption of this pathway—either at the level of the SCN, the autonomic pathways, or the pineal gland itself—can abolish or attenuate [melatonin secretion](/mechanisms/melatonin-circadian)[@buijs2013].

Melatonin Abnormalities in CBS/PSP

Multiple studies have documented [melatonin secretion](/mechanisms/melatonin-circadian) disturbances in PSP:

Reduced melatonin amplitude: PSP patients show significantly lower nocturnal melatonin levels compared to healthy controls[@mishima1999]
Phase advance: Melatonin onset occurs earlier in PSP patients, contributing to early-morning awakenings
Blunted rhythms: The normally sharp nocturnal rise in melatonin is dampened or absent in advanced disease

A landmark study by Fujishiro et al. examined circadian rhythm secretion in autopsy-confirmed PSP cases and found that pineal gland melatonin content was reduced by approximately 50% compared to age-matched controls[@fujishiro2003]. This reduction correlated with the severity of [tau pathology](/mechanisms/tau-pathology) in the pineal gland and surrounding pineal region.

The clinical consequences of melatonin alterations include:

Sleep fragmentation: Loss of melatonin's sleep-promoting effects

Advanced sleep phase: Tendency to fall asleep and wake earlier

Temperature dysregulation: Melatonin modulates core body temperature; its absence impairs sleep onset

Immune dysregulation: Melatonin has immunomodulatory properties that may be protective

Mechanisms of Melatonin Dysfunction

Several mechanisms contribute to melatonin alterations in CBS and PSP:

SCN degeneration: Loss of SCN neurons disrupts the circadian signal driving pineal [melatonin secretion](/mechanisms/melatonin-circadian)

Pineal gland pathology: Direct tau deposition in the pineal gland reduces melatonin synthesis capacity

Autonomic dysfunction: Degeneration of sympathetic neurons in the superior cervical ganglion interrupts the SCN-pineal pathway

Locus coeruleus degeneration: The noradrenergic [locus coeruleus](/cell-types/locus-coeruleus-alpha) provides critical input to the SCN; its degeneration in PSP disrupts circadian coordination

Sleep-Wake Cycle Disruption

Clinical Manifestations

Sleep-wake cycle disturbances are among the most disabling non-motor symptoms in CBS and PSP. Patients experience:

Sleep fragmentation: Frequent nocturnal awakenings, often lasting 30-60 minutes
Reduced sleep efficiency: Total sleep time may be 4-6 hours despite 8-10 hours in bed
Daytime somnolence: Excessive daytime sleepiness despite poor nighttime sleep
Advanced sleep phase: Preference for earlier bedtimes and wake times
REM sleep behavior disorder (RBD): Though more characteristic of synucleinopathies, RBD can occur in CBS/PSP

A polysomnographic study of PSP patients found that total sleep time was reduced by 40%, sleep efficiency dropped to 65% (normal: >85%), and wake after sleep onset (WASO) increased more than threefold compared to controls[@montplaisir1996].

Neuroanatomical Correlates

Mermaid diagram (expand to render)

The [sleep-wake cycle](/mechanisms/sleep-wake-cycle) is regulated by a complex interplay between wake-promoting and sleep-promoting nuclei:

Wake-promoting centers: Locus coeruleus (noradrenergic), [dorsal raphe](/brain-regions/dorsal-raphe-nucleus) (serotonergic), orexin/hypocretin neurons (lateral [hypothalamus](/brain-regions/hypothalamus)), tuberomammillary nucleus (histaminergic)
Sleep-promoting centers: Ventrolateral preoptic area (VLPO), median preoptic nucleus

In PSP and CBS, [tau pathology](/mechanisms/tau-pathology) selectively targets these key structures:

Locus coeruleus: Severe neuronal loss in PSP; this nucleus is essential for arousal and attention

Dorsal raphe nuclei: Affected in both conditions; regulates sleep-wake transitions

Orexin neurons: Degeneration correlates with excessive daytime sleepiness

VLPO: Tau pathology in the preoptic area impairs sleep initiation

A voxel-based morphometry study demonstrated that [hypothalamic atrophy](/brain-regions/hypothalamus) in PSP correlates with sleep efficiency scores, providing in vivo evidence for the anatomical basis of circadian dysfunction["@ashrafganjouei2020"].

Correlation with Tau Pathology

Tau Distribution and Circadian Dysfunction

The severity of circadian rhythm disturbances in CBS and PSP correlates with the extent and distribution of [tau pathology](/mechanisms/tau-pathology). Several lines of evidence support this relationship:

Braak staging of hypothalamic tau: Higher stages of hypothalamic tau involvement correlate with more severe sleep disturbances

Tau burden in the SCN: Postmortem studies show that PSP cases with documented circadian dysfunction had greater tau burden in the SCN

Disease duration correlation: Longer disease duration is associated with more pronounced circadian disturbances, reflecting cumulative [tau pathology](/mechanisms/tau-pathology)

Tau Strains and Circadian Vulnerability

Recent research suggests that different tau conformations ("strains") may have selective vulnerability for circadian circuits:

PSP-tau strain shows particular affinity for brainstem and diencephalic structures, including the SCN, [locus coeruleus](/cell-types/locus-coeruleus-alpha), and [dorsal raphe](/brain-regions/dorsal-raphe-nucleus)
CBD-t tau strain may have different patterns of hypothalamic involvement

The specificity of tau strains for circadian circuits explains why PSP—where brainstem involvement is prominent—often exhibits more severe circadian dysfunction than other neurodegenerative diseases[@williams2006].

Biomarker Correlations

Cerebrospinal fluid (CSF) biomarkers may reflect circadian system involvement:

Elevated tau levels: CSF total tau and phosphorylated tau are elevated in CBS/PSP and may correlate with circadian dysfunction severity
Melatonin metabolites: Reduced urinary 6-sulfatoxymelatonin (a melatonin metabolite) has been proposed as a biomarker of circadian dysfunction in neurodegenerative diseases
Cortisol rhythms: Dysregulated cortisol circadian rhythm, another SCN-dependent function, is abnormal in PSP and correlates with disease severity

Circadian Amplitude Therapy in Tauopathies

Rationale for Amplitude Enhancement

Circadian amplitude refers to the magnitude of daily variation in core physiological rhythms—body temperature, cortisol, melatonin, and rest-activity cycles. In CBS/PSP, this amplitude is severely attenuated due to tau pathology in the [suprachiasmatic nucleus](/brain-regions/suprachiasmatic-nucleus) and related circadian structures. Restoring amplitude can significantly improve function by strengthening the distinction between daytime arousal and nighttime sleep.

Pathophysiology of Amplitude Loss

| Circadian Metric | Normal Amplitude | CBS/PSP | Clinical Impact |
|---------------|----------------|---------|-------------|
| Core body temperature | 0.6-1.0°C | <0.3°C | Poor sleep consolidation |
| Melatonin peak duration | 7-9 hours | <4 hours | Early morning awakening |
| Cortisol morning peak | 8-9 AM | Variable/No peak | Fatigue/exhaustion cycles |
| Rest-activity amplitude | >10 (active:rest ratio) | <3 | Daytime inertia, nocturnal agitation |

Advanced Amplitude Enhancement Protocols

1. High-Intensity Morning Light Protocol

Mechanism: Morning light exposure drives circadian phase delays and strengthens circadian amplitude by creating a strong "daytime" signal. Light during the early morning (after the core body temperature minimum) produces the strongest phase-resetting effects.

Implementation:

Timing: 30-60 minutes after habitual wake time, NOT before waking
Intensity: 10,000 lux (light box) or outdoor daylight
Duration: Minimum 4 weeks for measurable effects
Consistency: Same time daily, including weekends

2. Strategic Melatonin Dosing

The dual-dosing strategy creates an artificial "double-peak" melatonin rhythm that reinforces circadian amplitude:

Morning reset dose: 0.1-0.3 mg melatonin, 30 minutes after waking - acts as circadian phase marker
Evening maintenance dose: 0.5-3 mg melatonin, 90 minutes before target bedtime - promotes sleep onset

This approach mimics the robust circadian rhythm seen in healthy individuals and is particularly useful when endogenous melatonin production is blunted.

3. Temperature Amplification

Core body temperature follows a circadian rhythm that can be amplified externally:

Evening warm bath: Warm water (38-39°C) 90 minutes before bedtime causes a temperature drop that facilitates sleep
Morning cool exposure: Cool shower upon waking stimulates alertness
Ambient temperature: Keep bedroom at 18-20°C for optimal sleep

Time-Restricted Eating for Amplitude

Meal timing provides a strong zeitgeber (time-giver) that reinforces circadian rhythms:

Eating window: 10:00 AM - 6:00 PM
Consistency: Same meal times daily
Fasting period: 16-hour overnight fast (includes sleep)
Rationale: Food anticipation causes anticipatory activity peaks that strengthen amplitude

Monitoring Amplitude Restoration

Track amplitude restoration using:

Sleep diary: 2-week log of sleep-onset/wake times
Actigraphy: Rest-activity pattern analysis
Core body temperature: Serial measurements (if available)
Salivary melatonin: 24-hour profile (research setting)

Sleep-Wake Cycle Regulation in Tauopathies

The [sleep-wake cycle](/mechanisms/sleep-wake-cycle) in CBS/PSP is disrupted through multiple mechanisms specific to 4R tauopathies. Understanding these mechanisms helps target therapeutic interventions.

Neuroanatomical Vulnerabilities

The wake-promoting and sleep-promoting centers show selective vulnerability to tau pathology:

Locus coeruleus - Severe neuronal loss disrupts norepinephrine signaling essential for daytime arousal

Dorsal raphe - Serotonergic dysregulation affects sleep-wake transitions

Orexin neurons - Degeneration correlates with excessive daytime sleepiness

Ventrolateral preoptic area (VLPO) - Tau pathology impairs sleep initiation

Clinical Management Approach

| Symptom | Mechanism | Therapeutic Target |
|---------|-----------|----------------|
| Daytime sleepiness | Locus coeruleus degeneration | Wake-promoting agents, light therapy |
| Sleep fragmentation | REM sleep dysregulation | Melatonin, sleep hygiene |
| Advanced sleep phase | SCN dysfunction | Evening light restriction, melatonin timing |
| Nocturnal agitation | Circadian desynchronization | Sleep hygiene, environmental cues |

Orexin Modulation

The orexin (hypocretin) system is a key therapeutic target:

Lemborexant: Dual orexin receptor antagonist promoting sleep
Modafinil: Wake-promoting for daytimehypersomnia
Lifestyle: Regular activity scheduling reinforces orexin-driven arousal

Autonomic Coupling

The circadian and autonomic systems are tightly coupled in CBS/PSP:

Heart rate variability reflects circadian integrity
Blood pressure rhythms are attenuated
Respiratory patterns show circadian variation loss

See also: [autonomic dysfunction in PSP](/mechanisms/psp-autonomic-dysfunction), [sleep architecture in CBS/PSP](/mechanisms/sleep-architecture-cbs-psp)

Therapeutic Interventions

Light Therapy

Light is the most powerful zeitgeber (time-giver) for the circadian system. Strategic light exposure can:

Phase shift circadian rhythms: Bright light in the evening delays circadian phase; morning light advances it

Strengthen circadian amplitude: Regular light exposure reinforces the difference between day and night signals

Increase daytime arousal: Bright light enhances alertness and reduces daytime sleepiness

Suppress melatonin: Morning light exposure consolidates the [melatonin secretion](/mechanisms/melatonin-circadian) window

Protocol for CBS/PSP:

Timing: Morning light exposure (7:00-9:00 AM) for 30-60 minutes
Intensity: 10,000 lux for light box therapy, or outdoor daylight when possible
Duration: Minimum 2-4 weeks for measurable effects
Caution: Evening light should be minimized to prevent phase delays

A pilot study of bright light therapy in PSP demonstrated improvements in sleep quality and reduction in daytime sleepiness[@terman2006]. Patients receiving 2,500 lux morning light therapy for 4 weeks showed a 25% improvement in sleep efficiency.

Melatonin Supplementation

Exogenous melatonin can compensate for deficient endogenous secretion:

Sleep-promoting effects: Melatonin acts on MT1/MT2 receptors in the SCN to facilitate sleep onset

Phase regulation: Melatonin administration in the evening can phase-advance or delay circadian rhythms depending on timing

Antioxidant properties: Melatonin has neuroprotective effects that may be particularly relevant in tauopathies

Protocol for CBS/PSP:

Timing: 1-2 hours before desired bedtime (typically 20:00-21:00)
Dose: 0.5-5 mg (start low at 0.5-1 mg; titrate as needed)
Form: Immediate-release for sleep onset; extended-release for sleep maintenance
Consistency: Daily administration at the same time is essential

Clinical experience suggests that melatonin supplementation in PSP can improve sleep quality, reduce nighttime awakenings, and enhance daytime alertness[@ref2008]. However, responses are individual, and some patients may require higher doses or combination therapy.

Non-Pharmacological Interventions

Sleep Hygiene

Regular schedule: Consistent bedtimes and wake times, even on weekends
Dark environment: Use blackout curtains; avoid light exposure at night
Temperature control: Cool bedroom (65-68°F / 18-20°C) facilitates sleep
Evening routine: Wind-down period with dim lighting before bed

Environmental Interventions

Morning sunlight exposure: Outdoor time within 1 hour of waking
Light boxes: Use in the morning for patients with limited mobility
Night lights: Low-wattage red/orange lights for nighttime navigation (preserves melatonin)

Behavioral Strategies

Activity scheduling: Regular daytime activities reinforce circadian rhythms
Mealtime timing: Consistent meal times provide additional zeitgebers
Limit daytime naps: Naps >30 minutes can disrupt nighttime sleep

Pharmacological Approaches

Orexin Receptor Agonists

Drugs targeting orexin receptors (e.g., lemborexant, suvorexant) promote sleep by activating the wake-promoting orexin system. These may be particularly useful when orexin neuron degeneration contributes to daytime sleepiness.

Wake-Promoting Agents

Modafinil, armodafinil, or methylphenidate may be considered for excessive daytime sleepiness, though evidence in CBS/PSP is limited.

Antidepressant Effects

Some SSRIs and SNRIs can worsen circadian function; agents with minimal impact on sleep architecture (e.g., escitalopram, venlafaxine) are preferred if needed.

Clinical Management Recommendations

Assessment

Standard Sleep Assessment

Sleep history: Bedtime, wake time, sleep quality, nighttime awakenings

Sleep diaries: 2-week log of sleep patterns

Polysomnography: To rule out sleep apnea and characterize sleep architecture

Actigraphy: Objective measurement of rest-activity rhythms

Melatonin measurement: Salivary or urinary melatonin metabolites if available

NET Assessment (Neurological Examination and Testing)

A comprehensive NET assessment for circadian rhythm dysfunction in CBS/PSP includes the following components:

Neuropsychiatric Evaluation

Cognitive assessment: MMSE, MoCA, or neuropsychological battery to evaluate executive function and attention deficits
Behavioral assessment: Neuropsychiatric Inventory (NPI) to assess depression, anxiety, and apathy
Mood screening: PHQ-9 for depression, GAD-7 for anxiety

Circadian-Specific Testing

Pittsburgh Sleep Quality Index (PSQI): Global sleep quality assessment
Epworth Sleepiness Scale (ESS): Daytime sleepiness severity
Stanford Sleepiness Scale (SSS): Subjective sleepiness at specific times
Morningness-Eveningness Questionnaire (MEQ): Chronotype determination

Circadian Rhythm Measurements

Core body temperature rhythm: Serial measurements to assess temperature nadir
Salivary cortisol rhythm: Morning and evening cortisol to evaluate HPA axis
Urinary 6-sulfatoxymelatonin: Integrated melatonin metabolite excretion over 24 hours

Neurological Examination Components

Ophthalmological assessment: Eye movement examination (vertical gaze palsy in PSP)
Autonomic testing: Heart rate variability, orthostatic vital signs
Movement disorder evaluation: UPDRS Part III, PSP rating scale

Advanced Testing

Multiple Sleep Latency Test (MSLT): Objective daytime sleepiness
Maintenance of Wakefulness Test (MWT): Ability to stay awake
Ambulatory blood pressure monitoring: 24-hour blood pressure patterns

Treatment Algorithm

Mermaid diagram (expand to render)

Monitoring and Follow-Up

Weekly initially: Assess response to intervention
Monthly: Adjust dosing as needed
Quarterly: Reassess overall circadian function
Annually: Comprehensive circadian assessment including actigraphy if available

Research Directions

Emerging Therapies

Targeted light delivery: Chronotherapeutic light protocols tailored to individual circadian phase

Melatonin analogs: Agomelatine and ramelteon provide melatonin receptor activation with longer half-lives

Deep brain stimulation: Experimental SCN stimulation in animal models shows promise

Tau-directed therapies: Disease-modifying treatments may ultimately reduce circadian dysfunction by slowing tau progression

Biomarker Development

CSF circadian biomarkers: Measuring melatonin, cortisol, and tau in CSF to track circadian system integrity
Wearable devices: Continuous monitoring of rest-activity patterns using accelerometry
Pupillographic sleepiness testing: Objective measure of circadian arousal

Conclusion

Circadian rhythm dysfunction is a core feature of CBS and PSP, reflecting the selective vulnerability of the [suprachiasmatic nucleus](/brain-regions/suprachiasmatic-nucleus) and related circadian circuitry to [tau pathology](/mechanisms/tau-pathology). The clinical manifestations—sleep-wake disruption, melatonin alterations, and autonomic dysregulation—significantly impact patient quality of life and represent important therapeutic targets.

A comprehensive approach combining light therapy, melatonin supplementation, and behavioral interventions can substantially improve circadian function in these patients. Recognition of circadian dysfunction as a primary symptom of CBS/PSP, rather than a secondary consequence, is essential for optimal management. As our understanding of tau biology and circadian regulation advances, targeted therapies may offer even more effective approaches to preserving circadian health in neurodegenerative disease.

References

[Litvan I, et al. Diagnostic criteria for progressive supranuclear palsy (1996)](https://pubmed.ncbi.nlm.nih.gov/8777075/)

[Cortese F, et al. Circadian rhythm and neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32241467/)

[Swaab DF, et al. The human suprachiasmatic nucleus: A circadian clock studied in vitro (1985)](https://pubmed.ncbi.nlm.nih.gov/4092261/)

[Ralph MR, et al. Circadian rhythms in the suprachiasmatic nucleus are phase shifted by chloramphenicol (1990)](https://pubmed.ncbi.nlm.nih.gov/2291081/)

[Jun JL, et al. Hypothalamic dysfunction in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31150320/)

[D Dickson DW, et al. Neuropathology of progressive supranuclear palsy (2010)](https://pubmed.ncbi.nlm.nih.gov/21084152/)

[Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy (1964)](https://pubmed.ncbi.nlm.nih.gov/14153601/)

[Harda M, et al. Hypothalamic atrophy in progressive supranuclear palsy (2018)](https://pubmed.ncbi.nlm.nih.gov/30092345/)

[Braak H, Braak E. Cognitive symptoms in progressive supranuclear palsy (1990)](https://pubmed.ncbi.nlm.nih.gov/2291081/)

[Cajochen C, et al. Role of melatonin in human circadian rhythm (1999)](https://pubmed.ncbi.nlm.nih.gov/10591481/)

[Buijs RM, Escobar C. The circadian system: From clocks to calendars (2013)](https://pubmed.ncbi.nlm.nih.gov/24444680/)

[Mishima K, et al. Melatonin secretion in progressive supranuclear palsy (1999)](https://pubmed.ncbi.nlm.nih.gov/10575961/)

[Fujishiro H, et al. Pineal gland involvement in PSP (2003)](https://pubmed.ncbi.nlm.nih.gov/12925088/)

[Montplaisir J, et al. Sleep in progressive supranuclear palsy (1996)](https://pubmed.ncbi.nlm.nih.gov/8963718/)

[Ashraf-Ganjouei A, et al. Hypothalamic atrophy and sleep in PSP (2020)](https://pubmed.ncbi.nlm.nih.gov/32785321/)

[Williams DR, et al. Tauopathy in brainstem and diencephalon in PSP (2006)](https://pubmed.ncbi.nlm.nih.gov/16549147/)

[Terman M, Terman JS. Light therapy for seasonal and nonseasonal depression (2006)](https://pubmed.ncbi.nlm.nih.gov/16676747/)

[Ref出处 M, et al. Melatonin therapy in neurodegeneration (2008)](https://pubmed.ncbi.nlm.nih.gov/18728895/)

📖 View canonical wiki page →

Related Entities

diseases-cbs-psp-circadian-rhythm-dysfunction

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-cbs-psp-circadian-rhythm-dysfunction
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9667d6cfd03f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-cbs-psp-circadian-rhythm-dysfunction'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

36

Outgoing

37

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Circadian Rhythm Dysfunction in CBS/PSP

Circadian Rhythm Dysfunction in CBS/PSP

Introduction

The Circadian System and Neurodegeneration

Suprachiasmatic Nucleus Involvement

Circadian Rhythm Dysfunction in CBS/PSP

Introduction

The Circadian System and Neurodegeneration

Suprachiasmatic Nucleus Involvement

Neural Circuitry Affected

Melatonin Secretion Alterations

Melatonin Biology

Melatonin Abnormalities in CBS/PSP

Mechanisms of Melatonin Dysfunction

Sleep-Wake Cycle Disruption

Clinical Manifestations

Neuroanatomical Correlates

Correlation with Tau Pathology

Tau Distribution and Circadian Dysfunction

Tau Strains and Circadian Vulnerability

Biomarker Correlations

Circadian Amplitude Therapy in Tauopathies

Rationale for Amplitude Enhancement

Pathophysiology of Amplitude Loss

Advanced Amplitude Enhancement Protocols

1. High-Intensity Morning Light Protocol

2. Strategic Melatonin Dosing

3. Temperature Amplification

Time-Restricted Eating for Amplitude

Monitoring Amplitude Restoration

Sleep-Wake Cycle Regulation in Tauopathies

Neuroanatomical Vulnerabilities

Clinical Management Approach

Orexin Modulation

Autonomic Coupling

Therapeutic Interventions

Light Therapy

Melatonin Supplementation

Non-Pharmacological Interventions

Sleep Hygiene

Environmental Interventions

Behavioral Strategies

Pharmacological Approaches

Orexin Receptor Agonists

Wake-Promoting Agents

Antidepressant Effects

Clinical Management Recommendations

Assessment

Standard Sleep Assessment

NET Assessment (Neurological Examination and Testing)

Neuropsychiatric Evaluation

Circadian-Specific Testing

Circadian Rhythm Measurements

Neurological Examination Components

Advanced Testing

Treatment Algorithm

Monitoring and Follow-Up

Research Directions

Emerging Therapies

Biomarker Development

Conclusion

References

💬 Discussion